DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ceritinib
Ceritinib
Clinical Response of the Novel Activating ALK-I1171T
ZYKADIA (Ceritinib) RATIONALE for INCLUSION in PA PROGRAM
Clinical Response of the Novel Activating ALK-I1171T Mutation In
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
ALK Tyrosine Kinase Inhibitors, 5.01.538
Zykadia (Ceritinib)
Systemic Therapy Update
Zykadia) for Metastatic Non-Small Cell Lung Cancer
Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
205755Orig1s000
Study Protocol & Schedule of Activities
Lung Cancer Agents – Unified Formulary
Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase
Dual Kinase Targeting in Leukemia
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Encephalic Leukocytoclastic Vasculitis During Treatment with Sunitinib for Renal Cell Carcinoma: a Case Report
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Top View
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Pharmacology Update
Bladder Cancer
Drug-Drug Interactions of Common Chemotherapeutic Agents And
Open Full Page
Efficacy of Ceritinib After Alectinib for ALK-Positive Non-Small Cell Lung
Cancer Drug Indications with Orphan Designation by the FDA (2008 - 2017) and Comparison with the EMA
NCCN Non-Small Cell Lung Cancer V.1.2018 – Meeting – June 16, 2017
The Potent ALK Inhibitor Brigatinib (AP26113)
Ceritinib: Drug Information
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Non–Small Cell Lung Cancer Erminia Massarelli and Vassiliki Papadimitrakopoulou
Expanding the Portfolio of Anti-ALK Weapons
205755Orig1s000
Comparisons of Non-Small Cell Lung Cancer Treatment Options: New Zealand and Australia Versus European Society for Medical Oncology (ESMO) Guidelines
Overview of Current Type I/II Kinase Inhibitors
Reimbursement Criteria for Frequently Requested Drugs
Adult Antiemetic Management of Chemotherapy-Induced Nausea
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
ZYKADIA® (Ceritinib) Capsules, for Oral Use Pancreatitis: Elevations of Lipase And/Or Amylase and Pancreatitis Can Occur
Oncology Agents Policy #: Rx.01.67
Oncology Therapy for the Generalist
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Original Article Clinical Observations of Sunitinib Combined with Docetaxel for Advanced Non-Small Cell Lung Cancer and Its Effects on Serum IL-6 and TNF-Α
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
Management of Acquired Resistance to ALK Inhibitors: Repeat Biopsy to Characterize Mechanisms of Resistance Does Not Significantly Impact Clinical Outcomes
Randomized, Multicenter, Phase Iii, Open
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
New Oncology Reimbursements in Belgium
Game Changers in Pediatric Cancer Jane De Lartigue, Phd
Tyrosine Kinase Inhibitors - Oral
EGFR Inhibitors May Induce Tumor Stemness
To Quantify the Small-Molecule Kinase Inhibitors Ceritinib, Dacomitinib
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
A Retrospective Study of Alectinib Versus Ceritinib in Patients With
Zykadia, INN-Ceritinib
Study Protocol and Results
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Overcoming EGFR Bypass Signal-Induced Acquired
EGFR Inhibitors May Induce Tumor Stemness
Role and Targeting of Anaplastic Lymphoma Kinase in Cancer
Download Product Insert (PDF)
Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
205755Orig1s000
Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology Julie M
Publication Agenda CHMP 07-10 December 2020
Pf-06463922) Monotherapy Versus Crizotinib Monotherapy in the First-Line Treatment of Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer
Systemic Therapy Update
HEM/ONC News by Devon Schuyler
Tyrosine Kinase Receptors in Oncology